Table 4.
Predictors for non-persistence to bisphosphonates in patients with rheumatoid arthritis
| Variables | Univariable | aMultivariable | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Dosing frequency weekly vs. monthly BPs | 2.16 (1.67–2.79) | <0.001 | 2.19 (1.69–2.83) | <0.001 |
| Seropositive RA | 0.69 (0.51–0.95) | 0.023 | 0.68 (0.49–0.92) | 0.014 |
| Disease duration ≥ 24 months | 0.69 (0.54–0.88) | 0.003 | - | - |
| Previous compression fracture | 1.44 (0.98–2.12) | 0.062 | - | - |
| Reimbursement for BPs | 0.85 (0.66–1.08) | 0.192 | - | - |
| Age, years | 0.99 (0.98–1.01) | 0.604 | - | - |
| Glucocorticoids use | 1.06 (0.72–1.55) | 0.763 | ||
| Calcium /vitamin D supplement | 1.08 (0.78–1.5) | 0.622 | ||
| Baseline DEXA | 0.84 (0.57–1.24) | 0.373 | ||
| DAS28-ESR | 1.02 (0.95–1.09) | 0.586 | ||
BPs Bisphosphonates, RA Rheumatoid arthritis, DEXA dual energy X-ray absorptiometry, DAS28-ESR disease activity score assessed using the 28-joint count for swelling and tenderness- erythrocyte sedimentation rate
aEstimated using multivariable backward logistic regression models including dosing frequency of BPs, seropositive RA, disease duration > 24 months, previous compression fracture, reimbursement for BPs and age